Clinical Trial Update: Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of H101 oncolytic virus with lenvatinib and toripalimab versus FOLFOX in patients with advanced biliary tract …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)
• H101 (oncolytic adenovirus H101)
• LENVIMA (lenvatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Fudan University | Conditions: Biliary Tract Cancer (BTC) | Phase 2 | Status: NOT_YET_RECRUITING